• Written by: (Investorideas.com newswire, breaking stock market
  • Thu, 19 Sep 2024
  •   United States

SAN DIEGO - September 19, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that, on September 9, 2024, the Medanta Institutional Ethics Committee (MIEC) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda (pembrolizumab) or Opdivo (nivolumab) (AEMD-2022-06 Hemopurifier Study).

Breaking Medical Technology News: Aethlon (NASDAQ: AEMD) Receives Ethics Committee Approval for Hemopurifier Cancer Trial in India